| MRD-negative patients, % (95% CI)a |
| DBTd |
63.7 (59.5- 67.8)b |
CASSIOPEIA (ITT
population) |
To determine proportion of patients achieving MRD negativity |
| BTd |
43.5 (39.3-47.8)b |
CASSIOPEIA (ITT
population) |
|
| HR applied to OS parametric extrapolation, HR (95% CI) |
| MRD- vs MRD+ |
0.60 (0.50-0.72)c |
Analysis conducted on Munshi et al[@172071] |
To estimate survival outcomes for MRD- BTd patients (applied to BTd MRD+) |
| DBTd MRD+ vs BTd MRD+ |
0.73 (0.40-1.35) |
CASSIOPEIA
(landmark analysis) |
To estimate survival outcomes for MRD+ DBTd patients (applied to BTd MRD+) |
| DBTd MRD- vs BTd MRD- |
0.41 (0.16-1.04) |
CASSIOPEIA
(landmark analysis) |
To estimate survival outcomes for MRD- DBTd patients (applied to BTd MRD-) |